ロード中...
Preclinical evaluation of VAX-IP, a novel bacterial minicell-based biopharmaceutical for nonmuscle invasive bladder cancer
The development of new therapies that can prevent recurrence and progression of nonmuscle invasive bladder cancer remains an unmet clinical need. The continued cost of monitoring and treatment of recurrent disease, along with its high prevalence and incidence rate, is a strain on healthcare economic...
保存先:
| 出版年: | Mol Ther Oncolytics |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4824562/ https://ncbi.nlm.nih.gov/pubmed/27119118 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mto.2016.4 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|